Navigation Links
FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
Date:9/10/2010

arter 2010. During this time, FASLODEX 250mg will still be available.

According to data from the U.S. National Cancer Institute, more than 207,000 American women will be diagnosed with breast cancer in 2010.(3) Approximately 155,000 women in the United States are currently living with metastatic breast cancer, and this number is projected to increase to nearly 162,000 by the year 2011.(4)

The CONFIRM study, presented for the first time at the annual San Antonio Breast Cancer Symposium (SABCS) in December 2009, showed FASLODEX 500mg reduced the risk of disease progression (assessed as progression free survival) by 20 percent (HR 0.80; 95% CI 0.68-0.94, p=0.006) when compared with FASLODEX 250mg. FASLODEX 500mg significantly increased median progression free survival to 6.5 months vs. 5.4 months with 250mg (p=0.006).

Objective Response Rates calculated in patients with measurable disease was not significantly different between FASLODEX 500mg (13.8%) and 250mg (14.6%) (HR=0.94; 95% CI: 0.57-1.55) (p=0.795).  Median overall survival was 25.1 months with FASLODEX 500mg and 22.8 months with 250mg (HR=0.84; 95% CI: 0.69-1.03) (p=0.091).  At the time of analysis, overall survival was not statistically significant. A pre-planned second survival analysis will occur as data mature when approximately 75% of patients have had an event.  

Important Safety Information About FASLODEX® (fulvestrant) Injection

FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.

Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants. FASLODEX is metabolized primarily in the liver. A 250-mg dose is recommended in patients with moderate hepatic impairment. F
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Pediatric Use of Chemical Poisoning Treatment
2. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
3. FDA Approves Vaccines for the 2010-2011 Influenza Season
4. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
5. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
6. U.S. FDA Approves Improved Performance of Riverain Medicals OnGuard Chest X-ray Computer-Aided Detection Technology
7. FDA Approves New Injectable Osteoporosis Treatment for Postmenopausal Women
8. FDA Approves New Treatment for Late-Onset Pompe Disease
9. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
10. U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
11. FDA Approves New Combination Product Oral Contraceptive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... Dec. 23, 2014  Advanced Medical Isotope Corporation ... primarily in the development of brachytherapy devices and ... announced that it has filed a de ... Administration ("FDA") for marketing clearance for its patented ... the U.S. Food, Drug and Cosmetic Act (the ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... BETHLEHEM, Pa., April 26, 2011 In collaboration ... for Anticancer Drug Research (CESAR) announced today that ... paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided ... non-small cell lung cancer (NSCLC).  The study will ...
... International Limited (NYSE: MR ), a leading developer, ... it will report its financial results for the first quarter ... May 9, 2011. Mindray,s management will hold an earnings conference ... Time (8:00 PM on May 10, 2011 Beijing/Hong Kong Time). ...
Cached Medicine Technology:Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 2Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 3Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 4Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 5Mindray to Report First Quarter 2011 Financial Results on May 9, 2011 2
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... will gather for the Experimental Biology 2008 meeting in ... of the annual meeting, now in its 18th year, ... research presentations and exhibits have been selected because of ... Scientists and clinicians from dozens of different disciplines, from ...
... Jim Reynolds, MD join executive team; Jerry Noyce announces ... ... HealthFitness (OTC,Bulletin Board: HFIT) announced today that John Griffin has ... the,company as chief medical officer and Jerry Noyce has retired as ...
... BEIJING, Feb. 4 /Xinhua-PRNewswire/ -- The Red Cross ... payment service provider in China, to,launch online donation ... make online donations for snow storm victims in ... http://www.yeepay.com/mlove ., (Logo: http://www.newscom.com/cgi-bin/prnh/20051211/CNM005 ...
... follows positive phase I data from novel product candidate ... the oral ... Amira Pharmaceuticals and,GlaxoSmithKline today announced they have entered ... FLAP,(5-Lipoxygenase Activating Protein ) inhibitors for the treatment of,respiratory ...
... more than 78% , , MONDAY, Feb. 4 (HealthDay News) -- ... a new study shows it may also ease the pain ... sugar-and-water solution will also ease parents, fears and boost immunization ... to get their children vaccinated," said study author Linda Hatfield, ...
... SAP Public Services, Inc.,a subsidiary of SAP ... Corbett as vice,president of its U.S. healthcare practice. ... sector and,government-driven initiatives to improve the quality and ... be responsible for growing,SAP,s business in the U.S. ...
Cached Medicine News:Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 2Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 3Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 4Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 5Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 6Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 2Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 3Health News:Red Cross Partners with YeePay on China Snow Disaster Relief 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 3Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 4Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 2Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 4Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 5
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
Medicine Products: